{"DataElement":{"publicId":"3228309","version":"1","preferredName":"Blinded Clinical Study And Randomized Trial Treatment Arm Dose Frequency","preferredDefinition":"The amount of medication and occurences a participant was randomized to.","longName":"BL_C_RAND_ARM_D_FREQ","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"2787850","version":"1","preferredName":"Blinded Clinical Study And Randomized Trial Pharmacologic Substance Administered","preferredDefinition":"A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s)._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._A study in which the participants are assigned by chance to separate groups that compare different treatments; neither the researchers nor the participants can choose which group.  Using chance to assign people to groups means that the groups will be similar and that the treatments they receive can be compared objectively.  At the time of the trial, it is not known which treatment is best. It is the patient's choice to be in a randomized trial._An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient (21 CFR 314.3(b))._The act of having given something (e.g., a medication or test).","longName":"BLND_RAND_TRL_PS_ADM","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2955173","version":"1","preferredName":"Blinded Clinical Study And Randomized Clinical Trial Pharmacologic Substance","preferredDefinition":"A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).:An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.:A study in which the participants are assigned by chance to separate groups that compare different treatments; neither the researchers nor the participants can choose which group.  Using chance to assign people to groups means that the groups will be similar and that the treatments they receive can be compared objectively.  At the time of the trial, it is not known which treatment is best. It is the patient's choice to be in a randomized trial.:A natural, synthetic or semi-synthetic substance including endogenous body substance used to diagnose, prevent, maintain, treat or analyze abnormal and normal biological functions in vivo or in vitro.","longName":"C70840:C37912:C15417:C1909","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinded Clinical Study","conceptCode":"C70840","definition":"A clinical study that is designed using a procedure in which one or more parties to the study [subject(s), investigator(s), monitor, or/and data analyst(s)] are kept unaware of the treatment assignment(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Randomized Clinical Trial","conceptCode":"C15417","definition":"Assignment of subjects by chance to groups that receive different treatments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacologic Substance","conceptCode":"C1909","definition":"Any natural, endogenously-derived, synthetic or semi-synthetic compound with pharmacologic activity. A pharmacologic substance has one or more specific mechanism of action(s) through which it exerts one or more effect(s) on the human or animal body. They can be used to potentially prevent, diagnose, treat or relieve symptoms of a disease. Formulation specific agents and some combination agents are also classified as pharmacologic substances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"766575D2-F2A3-0BF4-E040-BB89AD434032","latestVersionIndicator":"Yes","beginDate":"2009-10-20","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-10-20","modifiedBy":"ONEDATA","dateModified":"2009-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"57BDBBF2-E24F-68F2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-25","endDate":null,"createdBy":"LEATHERJ","dateCreated":"2008-09-25","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3228304","version":"1","preferredName":"Randomized Clinical Trial Protocol Treatment Arm Dose Frequency","preferredDefinition":"The amount of medication and occurences a participant was randomized to.","longName":"RND_C_TRL_ARM_D_FREQ","context":"DCP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Placebo","valueDescription":"Placebo","ValueMeaning":{"publicId":"3228305","version":"1","preferredName":"Placebo","longName":"3228305","preferredDefinition":"An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15C7F84-4B5D-4B63-E040-BB89AD432192","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A15C7F84-4B76-4B63-E040-BB89AD432192","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"ONEDATA","dateModified":"2011-04-20","deletedIndicator":"No"},{"value":"DHA","valueDescription":"Doconexent","ValueMeaning":{"publicId":"3623407","version":"1","preferredName":"Doconexent","longName":"3623407","preferredDefinition":"A polyunsaturated very long-chain fatty acid with a 22-carbon backbone and 6 double bonds, originating from the 3rd, 6th, 9th, 12th, 15th and 18th positions from the methyl end.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doconexent","conceptCode":"C68346","definition":"A polyunsaturated very long-chain fatty acid with a 22-carbon backbone and 6 double bonds, originating from the 3rd, 6th, 9th, 12th, 15th and 18th positions from the methyl end.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CCB9CF63-FF7A-864D-E040-BB89AD434A34","latestVersionIndicator":"Yes","beginDate":"2012-10-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2012-10-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CCB9CF63-FF93-864D-E040-BB89AD434A34","beginDate":"2012-10-23","endDate":null,"createdBy":"MAESKEB","dateCreated":"2012-10-23","modifiedBy":"ONEDATA","dateModified":"2012-10-23","deletedIndicator":"No"},{"value":"Aspirin 325 mg","valueDescription":"Aspirin Integer","ValueMeaning":{"publicId":"5508090","version":"1","preferredName":"Aspirin Integer","longName":"5508090","preferredDefinition":"An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.: A number with no fractional part, including the negative and positive numbers as well as zero.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspirin","conceptCode":"C287","definition":"An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E495B70-00E0-58C5-E053-F662850A6634","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3E497361-8F40-5422-E053-F662850A13E5","beginDate":"2016-10-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-10-07","modifiedBy":"ONEDATA","dateModified":"2016-10-07","deletedIndicator":"No"},{"value":"Naproxen 220 mg","valueDescription":"Naproxen Integer","ValueMeaning":{"publicId":"5508091","version":"1","preferredName":"Naproxen Integer","longName":"5508091","preferredDefinition":"A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.: A number with no fractional part, including the negative and positive numbers as well as zero.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Naproxen","conceptCode":"C680","definition":"A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E495B70-0106-58C5-E053-F662850A6634","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3E495B70-011F-58C5-E053-F662850A6634","beginDate":"2014-01-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-10-07","modifiedBy":"ONEDATA","dateModified":"2016-10-07","deletedIndicator":"No"},{"value":"Naproxen 440 mg","valueDescription":"Naproxen Integer","ValueMeaning":{"publicId":"5508092","version":"1","preferredName":"Naproxen Integer","longName":"5508092","preferredDefinition":"A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.: A number with no fractional part, including the negative and positive numbers as well as zero.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Naproxen","conceptCode":"C680","definition":"A propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities. Naproxen inhibits the activity of the enzymes cyclo-oxygenase I and II, resulting in a decreased formation of precursors of prostaglandins and thromboxanes. The resulting decrease in prostaglandin synthesis is responsible for the therapeutic effects of naproxen. Naproxen also causes a decrease in the formation of thromboxane A2 synthesis, by thromboxane synthase, thereby inhibiting platelet aggregation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E495B70-0129-58C5-E053-F662850A6634","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3E495B70-0141-58C5-E053-F662850A6634","beginDate":"2014-01-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-10-07","modifiedBy":"ONEDATA","dateModified":"2016-10-07","deletedIndicator":"No"},{"value":"Topical placebo gel","valueDescription":"Topical Placebo Gel","ValueMeaning":{"publicId":"6066854","version":"1","preferredName":"Topical Placebo Gel","longName":"6066854","preferredDefinition":"On the surface of the body.: An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.: Jelly like material formed by the coagulation of a colloidal liquid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topical","conceptCode":"C13344","definition":"On the surface of the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gel","conceptCode":"C45297","definition":"Jelly like material formed by the coagulation of a colloidal liquid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65078E4E-3188-58CC-E053-F662850A6A03","latestVersionIndicator":"Yes","beginDate":"2018-02-12","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2018-02-12","modifiedBy":"ONEDATA","dateModified":"2018-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65078E4E-31A1-58CC-E053-F662850A6A03","beginDate":"2018-02-12","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2018-02-12","modifiedBy":"ONEDATA","dateModified":"2018-02-12","deletedIndicator":"No"},{"value":"2mL(4mg) topical 4-OHT gel","valueDescription":"2mL(4mg) topical 4-OHT gel","ValueMeaning":{"publicId":"6066855","version":"1","preferredName":"2mL(4mg) topical 4-OHT gel","longName":"6066855","preferredDefinition":"2mL(4mg) topical 4-OHT gel","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65078E4E-31AB-58CC-E053-F662850A6A03","latestVersionIndicator":"Yes","beginDate":"2018-02-12","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2018-02-12","modifiedBy":"ONEDATA","dateModified":"2018-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65078E4E-31C4-58CC-E053-F662850A6A03","beginDate":"2018-02-12","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2018-02-12","modifiedBy":"ONEDATA","dateModified":"2018-02-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3228303","version":"1","preferredName":"Randomized Clinical Trial Protocol Treatment Arm Dose Frequency","preferredDefinition":"A study in which the participants are assigned by chance to separate groups that compare different treatments; neither the researchers nor the participants can choose which group.  Using chance to assign people to groups means that the groups will be similar and that the treatments they receive can be compared objectively.  At the time of the trial, it is not known which treatment is best. It is the patient's choice to be in a randomized trial.:A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.:The amount of medicine taken, or radiation given, at one time.:The number of occurrences of something within a given time period. (NCI)","longName":"C15417:C15538:C25488:C25515","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Randomized Clinical Trial","conceptCode":"C15417","definition":"Assignment of subjects by chance to groups that receive different treatments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Protocol Treatment Arm","conceptCode":"C15538","definition":"A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Temporal Frequency","conceptCode":"C25515","definition":"The number of occurrences of something within a given time period.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15C7F84-4B38-4B63-E040-BB89AD432192","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"ONEDATA","dateModified":"2011-04-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15C7F84-4B49-4B63-E040-BB89AD432192","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"ZHANGWE","dateModified":"2018-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2194255","version":"1","longName":"Type of Condition","context":"DCP","ClassificationSchemeItems":[{"publicId":"3528035","version":"1","longName":"Docosahexaenoic Acid","context":"DCP"}]},{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"4188651","version":"1","longName":"MDA2013-01-02","context":"DCP"},{"publicId":"5416571","version":"1","longName":"MDA2013-02-02","context":"DCP"},{"publicId":"5889176","version":"1","longName":"MDA2016-07-02","context":"DCP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Treatment Arm Participant Ran","type":"Preferred Question Text","description":"Treatment Arm Participant Randomized To:","url":null,"context":"DCP"},{"name":"DCP-Text-2","type":"Alternate Question Text","description":"Treatment Arm Participant Randomized To","url":null,"context":"DCP"}],"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15C7F84-4BEF-4B63-E040-BB89AD432192","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"COLBERTM","dateModified":"2020-04-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}